Drugs /

ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL)- and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.

Clinical Trials

View Clinical Trials for ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine

Ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).

CTAG1A Expression, CTAG1B Expression, and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine clinical trials.

Cancer and malignant solid tumor are the most common diseases being investigated in ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ny-Eso-1(157-165) Peptide-Pulsed Autologous Dendritic Cell Vaccine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ny-Eso-1(157-165) Peptide-Pulsed Autologous Dendritic Cell Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous ny-eso-1 (157-165) peptide-pulsed dc vaccine
NCIT ID [1]:
C114380

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.